65 related articles for article (PubMed ID: 26543081)
1. Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells.
Petrovic M; Simillion C; Kruzliak P; Sabo J; Heller M
Cancer Genomics Proteomics; 2015; 12(6):347-58. PubMed ID: 26543081
[TBL] [Abstract][Full Text] [Related]
2. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
3. iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.
Leong S; Nunez AC; Lin MZ; Crossett B; Christopherson RI; Baxter RC
J Proteome Res; 2012 Jul; 11(7):3561-72. PubMed ID: 22587632
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.
Bober P; Alexovic M; Talian I; Tomkova Z; Viscorova Z; Benckova M; Andrasina I; Ciccocioppo R; Petrovic D; Adamek M; Kruzliak P; Sabo J
J Cancer Res Clin Oncol; 2017 Jan; 143(1):35-42. PubMed ID: 27620743
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells.
Strong R; Nakanishi T; Ross D; Fenselau C
J Proteome Res; 2006 Sep; 5(9):2389-95. PubMed ID: 16944951
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity.
McDonald C; Muhlbauer J; Perlmutter G; Taparra K; Phelan SA
Int J Oncol; 2014 Jul; 45(1):219-26. PubMed ID: 24789097
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL.
Leong S; McKay MJ; Christopherson RI; Baxter RC
J Proteome Res; 2012 Feb; 11(2):1240-50. PubMed ID: 22133146
[TBL] [Abstract][Full Text] [Related]
10. Investigation of doxorubicin resistance in MCF-7 breast cancer cells using shot-gun comparative proteomics with proteolytic 18O labeling.
Brown KJ; Fenselau C
J Proteome Res; 2004; 3(3):455-62. PubMed ID: 15253426
[TBL] [Abstract][Full Text] [Related]
11. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
12. A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF‑7 breast cancer cells.
Sommer AK; Hermawan A; Ljepoja B; Fröhlich T; Arnold GJ; Wagner E; Roidl A
Int J Mol Med; 2018 Oct; 42(4):1987-1997. PubMed ID: 30066829
[TBL] [Abstract][Full Text] [Related]
13. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
Zhang D; Putti TC
Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Int J Cancer; 1996 Sep; 67(5):608-14. PubMed ID: 8782646
[TBL] [Abstract][Full Text] [Related]
17. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.
Shi Z; Yang WM; Chen LP; Yang DH; Zhou Q; Zhu J; Chen JJ; Huang RC; Chen ZS; Huang RP
Breast Cancer Res Treat; 2012 Oct; 135(3):737-47. PubMed ID: 22923236
[TBL] [Abstract][Full Text] [Related]
18. Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells.
Rahbar AM; Fenselau C
J Proteome Res; 2005; 4(6):2148-53. PubMed ID: 16335961
[TBL] [Abstract][Full Text] [Related]
19. Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells.
Chen ST; Pan TL; Tsai YC; Huang CM
Cancer Lett; 2002 Jul; 181(1):95-107. PubMed ID: 12430184
[TBL] [Abstract][Full Text] [Related]
20. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
